Deze pagina is automatisch vertaald en de nauwkeurigheid van de vertaling kan niet worden gegarandeerd. Raadpleeg de Engelse versie voor een brontekst.

A Fully Remote Feasibility Trial of Phenylbutyrate for SLC6A1-Related Disorders

24 september 2026 bijgewerkt door: Kristen Barbour, Scripps Translational Science Institute

A Site-Less Feasibility Trial of Phenylbutyrate for SLC6A1-Related Disorders

The purpose of this study is to evaluate the feasibility of a site-less (fully remote) clinical trial using phenylbutyrate for SLC6A1-related disorders. Study participants will receive treatment with phenylbutyrate, undergo electroencephalogram (EEG) monitoring, and complete laboratory testing. Caregivers will report seizure frequency, answer questionnaires, and report side effects.

Participants will be randomly assigned to one of two groups. Randomization is stratified by age band (<7 years vs. ≥7 years) and baseline seizure frequency (≤5 vs. >5 daily seizures). One group will begin treatment immediately; the other group will have a 6-week observation period before starting treatment. All participants will receive phenylbutyrate. Treatment lasts up to 18 weeks with the option to extend for up to 3 years. Follow-up occurs at 18 weeks. If extending treatment, additional follow-up occurs at 6 months, 1 year, and then annually.

Participation is completely voluntary. There is the risk of adverse events from the study drug, phenylbutyrate, including hospitalization from metabolic acidosis. There is the risk of loss of confidentiality of your medical and personal information collected for this study. This study does not replace emergency medical care.

This is a fully remote study. Participants may enroll from any U.S. state. No facility visit is required.

Studie Overzicht

Toestand

Werving

Conditie

Interventie / Behandeling

Gedetailleerde beschrijving

The purpose of this study is to determine whether a site-less (fully remote) clinical trial design, one conducted entirely remotely without a physical clinic site, is feasible for families affected by SLC6A1-related disorders. A secondary purpose is to explore the safety, tolerability, and preliminary effectiveness of phenylbutyrate in this population.

SLC6A1-related disorder is a rare genetic condition that causes epilepsy and intellectual disability. It is caused by variants in the SLC6A1 gene, which encodes a protein called GABA transporter 1 (GAT-1) that helps regulate the brain chemical gamma-aminobutyric acid (GABA). Phenylbutyrate is a medication that is Food and Drug Administration (FDA) -approved for a different condition (urea cycle disorders) and is being studied here for its potential antiseizure effects in SLC6A1-related disorders. Early studies have suggested that phenylbutyrate may reduce seizure frequency in some individuals with this condition, but it has not yet been studied in a controlled clinical trial. This study will help determine whether a larger, controlled trial is feasible using a site-less (fully remote) design and will provide early information about how well phenylbutyrate works and how well it is tolerated in this population.

Studietype

Ingrijpend

Inschrijving (Geschat)

20

Fase

  • Fase 2

Contacten en locaties

In dit gedeelte vindt u de contactgegevens van degenen die het onderzoek uitvoeren en informatie over waar dit onderzoek wordt uitgevoerd.

Studiecontact

Studie Locaties

    • California
      • San Diego, California, Verenigde Staten, 92130
        • Werving
        • Scripps Research Translational Institute
        • Contact:

Deelname Criteria

Onderzoekers zoeken naar mensen die aan een bepaalde beschrijving voldoen, de zogenaamde geschiktheidscriteria. Enkele voorbeelden van deze criteria zijn iemands algemene gezondheidstoestand of eerdere behandelingen.

Geschiktheidscriteria

Leeftijden die in aanmerking komen voor studie

2 jaar tot 60 jaar (Kind, Volwassen)

Accepteert gezonde vrijwilligers

Nee

Geslachten die in aanmerking komen voor studie

Allemaal

Beschrijving

Inclusion Criteria:

  • Confirmed diagnosis of SLC6A1-related disorder based on a pathogenic or likely pathogenic variant in the SLC6A1 gene
  • Age 2-60 years at time of consent
  • Active clinical seizures, defined as ≥4 seizures in the 4 weeks prior to enrollment
  • Seizures persisting despite an adequate trial of ≥2 prior antiseizure medications at therapeutic doses
  • Stable antiseizure medication regimen for ≥4 weeks prior to enrollment
  • Parent, legal guardian, or legally authorized representative (LAR) able to provide informed consent and participate in digital follow-up assessments
  • Local licensed physician identified for ordering laboratory testing, EEG, and clinical evaluation as needed
  • English-speaking caregiver for consent and study communication

Exclusion Criteria:

  • Larger 3p25 chromosomal deletion extending beyond SLC6A1 and SLC6A11 to encompass additional genes
  • Early-infantile developmental and epileptic encephalopathy (DEE) phenotype
  • Epileptic spasms within the 6 months prior to enrollment
  • Hepatic impairment (AST or ALT >2× the upper limit of normal)
  • Renal impairment (eGFR <60 mL/min/1.73m²)
  • Thrombocytopenia (platelet count <150 × 10³/μL)
  • Inborn errors of beta-oxidation
  • Pancreatic insufficiency or intestinal malabsorption
  • Known hypersensitivity to phenylbutyrate or any of its components
  • Participation in another interventional investigational study within 30 days or 5 half-lives of the investigational product, whichever is longer
  • Current use of alfentanil, quinidine, cyclosporine, or probenecid due to clinically significant interactions with phenylbutyrate based on CYP3A4 modulation
  • Pregnancy or breastfeeding
  • Any condition that in the investigator's judgment would interfere with study participation or safety monitoring

This is a fully remote study. Participants may enroll from any U.S. state. No facility visit is required.

Studie plan

Dit gedeelte bevat details van het studieplan, inclusief hoe de studie is opgezet en wat de studie meet.

Hoe is de studie opgezet?

Ontwerpdetails

  • Primair doel: Behandeling
  • Toewijzing: Gerandomiseerd
  • Interventioneel model: Parallelle opdracht
  • Masker: Geen (open label)

Wapens en interventies

Deelnemersgroep / Arm
Interventie / Behandeling
Experimenteel: Arm A (Immediate Start)

Arm A will receive immediate treatment with phenylbutyrate beginning week 0 through week 18.

Glycerol phenylbutyrate oral liquid (1.1 g/mL) administered orally three times daily with food or formula, or via gastrostomy or nasogastric tube when clinically indicated. The dose is titrated over 8 weeks from a starting dose of 3.6 mL/m²/day to a target maximum of 11.2 mL/m²/day (12.4 g/m²/day), not to exceed 17.5 mL/day total, based on body surface area. Dose adjustments are made based on tolerability and safety laboratory results. Drug is obtained through self-pay via Cost Plus pharmacy with direct home delivery, or through the participant's health insurance at a designated pharmacy.

Other Name(s): Ravicti; glycerol phenylbutyrate oral liquid; GPB; 4-phenylbutyrate; 4-PBA

Actieve vergelijker: Arm B (Delayed Start)

Arm B will have a delayed start with an observation period weeks 0-6 followed by treatment beginning at week 6 through week 18.

Glycerol phenylbutyrate oral liquid (1.1 g/mL) administered orally three times daily with food or formula, or via gastrostomy or nasogastric tube when clinically indicated. The dose is titrated over 8 weeks from a starting dose of 3.6 mL/m²/day to a target maximum of 11.2 mL/m²/day (12.4 g/m²/day), not to exceed 17.5 mL/day total, based on body surface area. Dose adjustments are made based on tolerability and safety laboratory results. Drug is obtained through self-pay via Cost Plus pharmacy with direct home delivery, or through the participant's health insurance at a designated pharmacy.

Other Name(s): Ravicti; glycerol phenylbutyrate oral liquid; GPB; 4-phenylbutyrate; 4-PBA

Wat meet het onderzoek?

Primaire uitkomstmaten

Uitkomstmaat
Maatregel Beschrijving
Tijdsspanne
Recruitment efficiency
Tijdsspanne: From study opening through end of enrollment (approximately 2 years)

Number of participants enrolled and time from first contact to consent, averaged across the enrollment period. Target: ≥20 participants enrolled over 24 months.

From study opening through end of enrollment (approximately 2 years)
Protocol adherence: seizure diary completion
Tijdsspanne: Weeks 0-18

Proportion of weekly seizure diary entries completed at scheduled intervals across the 18-week assessment period. Target: ≥80% of scheduled entries completed.

Weeks 0-18
Protocol adherence: Electroencephalogram (EEG) completion
Tijdsspanne: Baseline, week 6 and week 18

Proportion of participants completing baseline, week 6, and 18-week EEG as specified by protocol. Target: ≥80%.

Baseline, week 6 and week 18
Protocol adherence: side effect questionnaire completion
Tijdsspanne: From treatment initiation through week 18

Proportion of scheduled side effect questionnaires completed at protocol-specified intervals from treatment initiation through week 18. Target: ≥80%.

From treatment initiation through week 18
Protocol adherence: safety laboratory completion
Tijdsspanne: 6 weeks after treatment initiation

Proportion of participants completing scheduled safety laboratory testing at 6 weeks after treatment initiation. Target: ≥80%.

6 weeks after treatment initiation
Retention
Tijdsspanne: Week 18

Proportion of enrolled participants completing the 18-week assessment period without voluntary or involuntary withdrawal. Target: ≥80%.

Week 18
Caregiver satisfaction: overall satisfaction
Tijdsspanne: Week 18

Median score on User Experience Questionnaire item Q1 assessing overall satisfaction with remote clinical trial participation. Scale 1-5 (1=very dissatisfied, 5=very satisfied). Target: median ≥4.

Week 18
Caregiver satisfaction: acceptability
Tijdsspanne: Week 18

Proportion of caregivers responding "Yes" to User Experience Questionnaire item Q2 asking whether they would recommend participating in a remote clinical trial to other families. Target: ≥80%.

Week 18
Caregiver satisfaction: fit with daily routine
Tijdsspanne: Week 18

Median score on User Experience Questionnaire item Q3 assessing whether the study fit well into the family's daily routine. Scale 1-5 (1=not at all, 5=completely). Target: median ≥4.

Week 18
Caregiver satisfaction: clarity of study procedures
Tijdsspanne: Week 18

Median score on User Experience Questionnaire item Q4 assessing ease of understanding study procedures and requirements. Scale 1-5 (1=very difficult, 5=very easy). Target: median ≥4.

Week 18
Caregiver satisfaction: time burden
Tijdsspanne: Week 18

Median score on User Experience Questionnaire item Q5 assessing ease of finding time to complete study tasks. Scale 1-5 (1=very difficult, 5=very easy). Target: median ≥4.

Week 18
Caregiver satisfaction: study team communication
Tijdsspanne: Week 18

Median score on User Experience Questionnaire item Q6 assessing clarity and helpfulness of study team communication. Scale 1-5 (1=not at all clear/helpful, 5=extremely clear/helpful). Target: median ≥4.

Week 18
Caregiver satisfaction: adequacy of remote safety monitoring
Tijdsspanne: Week 18

Median score on User Experience Questionnaire item Q7 assessing whether the participant's safety was adequately monitored during the remote trial. Scale 1-5 (1=not at all, 5=completely). Target: median ≥4.

Week 18
Caregiver satisfaction: access to medical support
Tijdsspanne: Week 18

Median score on User Experience Questionnaire item Q8 assessing ease of accessing medical support or advice when needed. Scale 1-5 (1=very difficult, 5=very easy). Target: median ≥4.

Week 18
Caregiver satisfaction: Research Electronic Data Capture (REDCap) usability
Tijdsspanne: Week 18

Median score on User Experience Questionnaire item Q9 assessing comfort using the REDCap platform for study participation. Scale 1-5 (1=very uncomfortable, 5=very comfortable). Target: median ≥4.

Week 18
Caregiver satisfaction: instructional video usefulness
Tijdsspanne: Week 18

Median score on User Experience Questionnaire item Q10 assessing usefulness of instructional videos provided through REDCap. Scale 1-5 (1=not at all useful, 5=extremely useful). Target: median ≥4.

Week 18
Caregiver satisfaction: optional phone call helpfulness
Tijdsspanne: 4 weeks after treatment initiation

Median score on User Experience Questionnaire item Q12 among participants who participated in the optional phone call at 4 weeks after treatment initiation (Q11=Yes). Scale 1-5 (1=not at all helpful, 5=extremely helpful). Proportion participating reported separately. Target: median ≥4 among participants.

4 weeks after treatment initiation
Caregiver experience: facilitators and barriers
Tijdsspanne: Week 18

Thematic summary of free-text responses to User Experience Questionnaire items Q13 (what participants liked most) and Q14 (challenges faced). Analyzed qualitatively to identify themes relevant to remote trial design.

Week 18

Secundaire uitkomstmaten

Uitkomstmaat
Maatregel Beschrijving
Tijdsspanne
Seizure frequency: percent change from baseline
Tijdsspanne: Baseline through week 18

Percent change in average weekly seizure frequency from the baseline observation period to weeks 14-18 of treatment (stable dose period), based on caregiver-completed seizure diaries. Analyzed descriptively.

Baseline through week 18
Seizure frequency: responder rate
Tijdsspanne: Baseline through week 18

Proportion of participants achieving ≥50% reduction in average weekly seizure frequency from baseline to the stable dose period (weeks 14-18 of treatment). Analyzed descriptively.

Baseline through week 18
Caregiver Global Impression of Change (CGIC)
Tijdsspanne: Week 18

Caregiver-rated global impression of change since starting phenylbutyrate, assessed using a 7-point scale (1=very much improved, 7=very much worse). Analyzed descriptively.

Week 18
Adaptive behavior: Vineland Adaptive Behavior Scales, Third Edition (VABS-3) composite score
Tijdsspanne: Baseline and week 18

Change in VABS-3 Adaptive Behavior Composite score from baseline to week 18. Standard scores range 20-160; higher scores indicate better adaptive functioning. Analyzed descriptively.

Baseline and week 18
Behavior: Aberrant Behavior Checklist Community Version
Tijdsspanne: Baseline and Week 18

Change in total score and subscale scores (Irritability/Agitation, Lethargy/Social Withdrawal, Stereotypic Behavior, Hyperactivity/Noncompliance, Inappropriate Speech) from baseline to week 18. Total scores range 0-174; higher scores indicate more frequent or severe behavioral difficulties. Analyzed descriptively.

Baseline and Week 18
Quality of life: QI-Disability score
Tijdsspanne: Baseline and week 18

Change in Quality of Life Inventory-Disability (QI-Disability) total score from baseline to week 18. Scores range 0-100; higher scores indicate better quality of life. Analyzed descriptively.

Baseline and week 18
Medication Burden
Tijdsspanne: Baseline and Week 18

Change in the number of concomitant antiseizure medications (not counting glycerol phenylbutyrate) from baseline to week 18, captured via weekly seizure diary. Analyzed descriptively.

Baseline and Week 18
Safety and tolerability: adverse events
Tijdsspanne: From treatment initiation through week 18

Frequency and severity of adverse events, serious adverse events, dose interruptions, and discontinuations throughout the study period. Summarized descriptively by event type, severity, causality, and outcome.

From treatment initiation through week 18
Safety and tolerability: laboratory values
Tijdsspanne: 6 weeks after treatment initiation

Proportion of 6 week post-treatment initiation safety laboratory values that are outside pre-specified thresholds reported descriptively, including phenylacetate level > 500 µg/mL, phenylacetic acid-to-phenylacetylglutamine (PAA-to-PAGN) ratio > 1.5, bicarbonate level < 17 mEq/L, anion gap > 12 mEq/L, urine pH < 5.5, the combination of low carnitine (total carnitine level < 30 µmol/L OR free carnitine level < 20 µmol/L) PLUS an elevated esterified-to-free carnitine ratio > 0.4, and ALT or AST (exceeds 3× the upper limit of normal with symptoms, or exceeds 5× the upper limit of normal without symptoms). Each parameter is reported separately as the proportion of participants with values outside pre-specified thresholds.

6 weeks after treatment initiation
EEG: Delta spectral power
Tijdsspanne: Baseline and Week 18

Change in delta-frequency (2.5-4 Hz) EEG spectral power from baseline to week 18, calculated at 1-second intervals across 18 channel pairs in the double banana montage, averaged across channels and the analyzed epoch. Analyzed descriptively as an exploratory biomarker of treatment response.

Baseline and Week 18
EEG: Delta-frequency autocorrelation
Tijdsspanne: Baseline and Week 18

Change in EEG autocorrelation at lags corresponding to 2.5-4 Hz from baseline to week 18, calculated at 1-second intervals across 18 channel pairs in the double banana montage, averaged across channels and the analyzed epoch. Analyzed descriptively.

Baseline and Week 18
EEG: Spectral entropy
Tijdsspanne: Baseline and Week 18

Change in broadband (0-30 Hz) EEG spectral entropy from baseline to week 18, calculated at 1-second intervals across 18 channel pairs in the double banana montage, averaged across channels and the analyzed epoch. Analyzed descriptively.

Baseline and Week 18
EEG: Combination of three measures
Tijdsspanne: Baseline and Week 18

Proportion of 1-second EEG segments meeting all three pre-specified thresholds simultaneously (delta power >105,000 μV², autocorrelation >0.410, spectral entropy ≤3.16) in ≥3 channels, compared from baseline to week 18. Analyzed descriptively as an exploratory biomarker outcome.

Baseline and Week 18
Concurrent randomized seizure comparison
Tijdsspanne: Week 6

Proportion of participants achieving ≥50% seizure reduction in Arm A (on treatment) versus Arm B (observation period) at week 6, reported as absolute risk difference, relative risk reduction, and number needed to treat, with 95% confidence intervals. Quantitative EEG measures (delta-frequency spectral power, autocorrelation at 2.5-4 Hz lags, and broadband spectral entropy) will be compared between arms at week 6 as an exploratory biomarker. Analyzed descriptively.

Week 6
Arm A within-person early vs. stable dose seizure comparison
Tijdsspanne: Weeks 0-2 and weeks 14-18

Mean weekly seizure frequency during early treatment (weeks 0-2) compared to the stable dose period (weeks 14-18) in Arm A participants. Analyzed descriptively.

Weeks 0-2 and weeks 14-18
Arm B within-person seizure change
Tijdsspanne: Weeks 0-6 and weeks 12-18 of treatment

Seizure frequency trajectory in Arm B, estimated using a segmented regression model assessing whether the pre-treatment slope is flat and characterizing the post-treatment slope through the stable dose period (weeks 12-18). Analyzed descriptively.

Weeks 0-6 and weeks 12-18 of treatment
Trajectory replication across arms
Tijdsspanne: Weeks 0-18

Comparison of post-treatment slopes from the segmented regression model in Arm A and Arm B, offset by 6 weeks, assessing whether the two arms show comparable seizure frequency trajectories following treatment initiation. Analyzed descriptively.

Weeks 0-18

Medewerkers en onderzoekers

Hier vindt u mensen en organisaties die betrokken zijn bij dit onderzoek.

Onderzoekers

  • Hoofdonderzoeker: Kristen Barbour, MD, This is a fully remote study. Participants may enroll from any U.S. state. No facility visit is required.

Studie record data

Deze datums volgen de voortgang van het onderzoeksdossier en de samenvatting van de ingediende resultaten bij ClinicalTrials.gov. Studieverslagen en gerapporteerde resultaten worden beoordeeld door de National Library of Medicine (NLM) om er zeker van te zijn dat ze voldoen aan specifieke kwaliteitscontrolenormen voordat ze op de openbare website worden geplaatst.

Bestudeer belangrijke data

Studie start (Geschat)

1 oktober 2026

Primaire voltooiing (Geschat)

1 maart 2029

Studie voltooiing (Geschat)

1 oktober 2032

Studieregistratiedata

Eerst ingediend

9 april 2026

Eerst ingediend dat voldeed aan de QC-criteria

24 september 2026

Eerst geplaatst (Werkelijk)

29 september 2026

Updates van studierecords

Laatste update geplaatst (Werkelijk)

29 september 2026

Laatste update ingediend die voldeed aan QC-criteria

24 september 2026

Laatst geverifieerd

1 september 2026

Meer informatie

Termen gerelateerd aan deze studie

Plan Individuele Deelnemersgegevens (IPD)

Bent u van plan om gegevens van individuele deelnemers (IPD) te delen?

NEE

Informatie over medicijnen en apparaten, studiedocumenten

Bestudeert een door de Amerikaanse FDA gereguleerd geneesmiddel

Ja

Bestudeert een door de Amerikaanse FDA gereguleerd apparaatproduct

Nee

Deze informatie is zonder wijzigingen rechtstreeks van de website clinicaltrials.gov gehaald. Als u verzoeken heeft om uw onderzoeksgegevens te wijzigen, te verwijderen of bij te werken, neem dan contact op met register@clinicaltrials.gov. Zodra er een wijziging wordt doorgevoerd op clinicaltrials.gov, wordt deze ook automatisch bijgewerkt op onze website .

Abonneren